Purpose: To determine the impact on duration of mechanical ventilation (MV) and the need for reintubation after changing from intravenous (IV) to oral phosphate formulations, in response to a national shortage of IV phosphate. Methods: A retrospective study was performed in adult patients who required MV for at least 48 hours. Results: A total of 136 patients were included, with 68 patients in both the restricted phosphate group and unrestricted phosphate groups. There was no difference in the cumulative phosphate supplementation received (IV and oral) between groups (P = .08). The overall mean serum phosphorus concentration in unrestricted vs restricted group was 3.0 vs 2.9 mg/dL, respectively (P = .24), and the phosphorus concentration was not significantly different between groups during the first 21 days of the study (P = .24). The median MV-free hours in the unrestricted group was 462 hours compared with 507 hours in the restricted group (P = .16), and 9 (13.2%) of patients in each group required reintubation (P = .99). There was no significant difference in mortality, or hospital, or intensive care unit (ICU) length of stay. Conclusions: No difference in MV-free hours or need for reintubation was observed after a national shortage requiring the restriction of IV phosphate supplementation. Oral phosphate replacement is a safe and an efficient alternative.
Introduction
Phosphorus is a vital component of the lipid bilayer of cell membranes and has an integral role in many physiological processes, such as cell integrity, cellular metabolism, and the clotting cascade. Derangements in phosphorus concentrations occur as a result of 3 main causes: decreased intestinal absorption, internal redistribution, and increased urinary excretion [1] . A significant intracellular shift of phosphorus is seen as a consequence of many conditions such as refeeding syndrome, recovery from diabetic ketoacidosis, respiratory alkalosis, hormonal agents (such as insulin, glucagon, and β-2 receptor agonists), and rapid cell proliferation [1, 2] . The incidence of hypophosphatemia varies widely depending on the patient population, from 0.2% in general medical patients up to 80% in patients with severe sepsis [1] .
Clinical manifestations of hypophosphatemia are broad and range from mild to life-threatening. These include decreased myocardial contractility, neurologic dysfunction, muscle weakness, tissue hypoxia, and death [1, 3] . Several studies have demonstrated that hypophosphatemia is also associated with impaired diaphragmatic contractility, acute respiratory failure, and failure-to-wean from mechanical ventilation (MV) [4] [5] [6] .
In 1988, Aubier and colleagues [4] first reported that hypophosphatemia impairs the contractility of the diaphragm during acute respiratory failure. Shortly after this study was completed, Gravelyn and colleagues [5] described a relationship between the degree of hypophosphatemia and the extent of respiratory weakness. Finally, a prospective observational study in 2010 by Alsumrain and colleagues [6] reported an association between hypophosphatemia and failure-to-wean from MV when compared with patients with normal serum phosphorus concentrations.
In December 2012, manufacturers of injectable sodium and potassium phosphate formulations reported a critical shortage of these products. With recommendations from the American Society of HealthSystem Pharmacists and American Society for Parenteral and Enteral Nutrition, our institution developed a protocol for management of hypophosphatemia during a critical shortage of injectable sodium and potassium phosphate as described below. The purpose of this study was to evaluate the management of hypophosphatemia while Journal of Critical Care 39 (2017) [31] [32] [33] [34] [35] determining the effect on duration of MV and need for reintubation in adult critically ill patients. Our 2 main hypotheses were as follows: (1) oral and enteral phosphate replacement is as effective as injectable forms for increasing phosphorus concentrations, and (2) route of phosphorus supplementation is not associated with duration of MV.
Methods

Study design and participants
A single-center, retrospective preimplementation and postimplementation investigational study was performed to assess the effects of restricting intravenous (IV) phosphate supplementation for the management of hypophosphatemia to any patient with a serum phosphorus concentration less than 1.5 mg/dL and to patients with a serum phosphorus concentration between 1.5 and 2 mg/dL where no other oral or enteral medications were prescribed and the effect on MV duration and need for reintubation in a critically ill population.
Adult patients older than 18 years admitted to intensive care unit (ICU) that required MV for at least 48 hours were eligible for inclusion. Patients in the unrestricted phosphate group were admitted between July and December 2012 (admitted before the IV phosphate restrictions), whereas those in the restricted phosphate group were admitted between July and December of 2013 (admitted after the IV phosphate restrictions were in place). Patients were excluded if required intubation for airway protection (after a stroke, severe traumatic brain injury, or alcohol withdrawal), admitted from an outside hospital and receiving MV, admitted with tracheostomy, had chronic respiratory failure (due to amyotrophic lateral sclerosis, end-stage lung disease, lung transplant, Guillain-Barre, or myasthenia gravis), received venovenous hemofiltration, admitted with DKA, required extracorporeal membrane oxygenation, or require MV for longer than 28 days. In addition, pregnant patients and prisoners were excluded.
Hypophosphatemia protocol
Beginning in April 2013 at our institution, orders for injectable phosphate in adult patients were automatically changed to oral or enteral phosphate replacement per an institution approved protocol in the following situations: sodium phosphate therapy during continuous renal replacement therapy, phosphate replacement in any patient with a serum phosphorus less than 1.5 mg/dL, and phosphate replacement in any patient with a serum phosphorus of 1.5 to 2 mg/dL where no other oral or enteral medications are currently prescribed.
Patients who were unable to receive phosphate supplementation by mouth received a liquid formulation via an enteral access device. Administration of phosphate supplementation via an enteral access device is standard of care in the critically ill and was considered equivalent to oral supplementation.
Outcomes
The primary outcome of this study was MV-free hours before and after implementation of criteria for use for IV phosphate. Mechanical ventilationfree hours were defined as the number of hours from study days 1 (time of successful extubation in a patient requiring ventilator support ≥48 hours) to 28 of which a patient breathed without assistance if the period of breathing without invasive respiratory support totaled at least 48 consecutive hours. If a patient died before the completion of the 28th day or required more than 28 days of MV, the value assigned was zero. In the event of reintubation, all periods without MV were considered MV-free hours if it was after a successful extubation [7] . Secondary outcomes included the average serum phosphate concentrations, hospital and ICU lengths of stay, all-cause mortality until study day 28, and the need for reintubation.
Data on baseline demographic and clinical characteristics included age, sex, race, body mass index, hospital and ICU length of stay, admitting service and location, University Health Consortium Expected Mortality Risk Score, total daily amount of phosphate supplementation received including route of administration, and outcomes including the duration of MV, need for reintubation, and daily serum phosphate concentrations.
The investigational review board at University of Florida approved this study.
Statistical analysis
Normally distributed continuous baseline characteristics were described using means and SDs, and skewed data were described using medians and interquartile ranges (IQRs). Categorical baseline characteristics were described with numbers and proportions.
Mean phosphorus concentrations during the first 21 days of the study were compared between groups using repeated-measures analysis of variance. The primary outcome, ventilator-free hours, was analyzed using the Student t test. Time-to-event data (time to extubation) were compared using log-rank tests and presented as Kaplan-Meier curves.
All statistical analyses were performed using SAS (v9.4; SAS, Cary, NC), with a 2-sided P value less than .05 considered to be statistically significant.
Results
A total of 1235 patients were assessed for eligibility (755 patients in the restricted IV phosphate group and 480 patients in the unrestricted phosphate group). After exclusion criteria had been applied, 136 patients were included in the final analysis (68 in the restricted IV phosphate group and 68 in the unrestricted phosphate group; Fig. 1 ). Baseline characteristics were comparable between the 2 groups (Table 1) .
In the restricted phosphate group, 96% of patients received oral or enteral phosphate supplementation compared with only 47% in the unrestricted group (P b .001), and 22% of patients received IV phosphate supplementation compared with 88% in the unrestricted group (P b .001). Patients in the restricted IV phosphate group received a significantly higher amount of oral or enteral phosphate supplementation, but there was no difference in the cumulative phosphate supplementation received (IV, oral, and enteral; Table 2 ).
Mechanical ventilation-free hours (P = .16) did not differ significantly between the 2 groups ( Table 2 ). The median (IQR) duration of MV was 142 (77-236) hours in the restricted phosphate group compared with 156 (95-293) hours in the unrestricted group (log-rank P = .20; Fig. 2 ).
The need for reintubation (P = .99) and the time between extubation and reintubation (P = .37) did not differ between the 2 groups ( Table 2 ). All patients in this study were reintubated for respiratory insufficiency or failure.
The 2 groups also had similar ICU and hospital length of stays and inhospital mortality rates (Table 2 ). There was no statistical difference in the mean phosphate concentration throughout the study between the restricted and unrestricted IV phosphate groups (P = .24; Fig. 3 ).
Discussion
Our study is the first to report that after a critical shortage of injectable phosphate products, there were no significant effects on the duration of MV, the need for reintubation, or average serum phosphate concentration in adult critically ill patients after implementing the criteria for use for IV phosphate due to a national shortage.
Hypophosphatemia and other electrolyte abnormalities causing respiratory failure have been well described in previous literature, impairing diaphragmatic pressures, contractility, and ability to wean from MV [4] [5] [6] . Although many of the previous studies found phosphate repletion improved respiratory muscle strength, there have been no studies to show that phosphate repletion was associated with improving MV-free time or mortality rates [8] .
There was no significant difference in the median serum phosphorus concentration or cumulative phosphate supplementation, indicating that the use of an oral or enteral agent was safe and effective in our critically ill patient population, despite differences in the bioavailabilty of oral or enteral and IV phosphate. A difference in MV-free time may be observed in future studies if the comparator groups have significantly different average serum phosphorus concentrations. In our study, severe hypophosphatemia (serum phosphate concentration b1 mg/dL) occurred only twice, and we were unable to perform statistical comparisons of this small cohort. We believe that the incidence of severe hypophosphatemia infrequently occurred in our study because of our routine electrolyte monitoring and aggressive electrolyte repletion protocols for our critically ill patients.
Previous studies have also reported an association with hypophosphatemia and increased mortality and correlation with the severity of hypophosphatemia and higher mortality rates [9] . In our study, severe hypophosphatemia was rare, which could explain why the overall mortality rate observed in our study was smaller than what has been reported in other trials and why there was no difference in mortality between the 2 groups [9] .
The same number of patients in each group required reintubation and MV in our study. The reintubation rate in our study (13.2%) is similar to what has been observed in other trials, which suggests that the protocol our institution follows to determine if a patient can be extubated and liberated from MV is both safe and effective [10] .
To our knowledge, this is the first study to examine the efficacy of oral or enteral and injectable electrolyte supplementation. Multiple studies have confirmed that the use of injectable phosphates is safe and efficacious. However, there is no previous trial to determine which route is superior [11] . There are currently no guidelines that specify the optimal route of phosphate repletion; however, based on the results of this study, mild or moderate (serum phosphate N2 mg/dL) hypophosphatemia can be treated with oral or enteral supplementation. In severe hypophosphatemia, treatment with an injectable phosphate product may be necessary, especially in those patients who are unable to tolerate or ingest oral or enteral medications [12] .
This study was undertaken at a single, large academic medical center and may not be representative of other hospitals in the United States with different protocols for phosphate replacement. Due to the retrospective design of our study, we did not perform an a priori power collection and therefore cannot rule out the possibility of a type II error. Many factors are associated with MV-free hours, of which many are ____ Unrestricted IV Phosphate Group (n = 68) ____ Restricted IV Phosphate Group (n = 68) Fig. 3 . Daily mean phosphorus concentrations (mg/dL) for the first 21 days of the study. Log-rank P = .20 Fig. 2 . Kaplan-Meier analysis of the proportion of patients remaining intubated during the 28-day study.
challenging to control. One of these factors includes the use of sedative medications. Our institution's current sedation protocol was developed during the study period, and we were unable to compare the patient's level of sedation during each study period to assess this confounding variable on the duration of MV. In addition, in both periods, there was no standard phosphate replacement protocol and physicians were free to order any amount of phosphate, causing variability among the resulting serum phosphate concentrations. We did not collect data regarding adherence to our institutional protocol of reassessing phosphate concentration after initial phosphorus repletion with either oral, enteral, or IV phosphate. We also did not collect data on the receipt of other medications that could have altered serum phosphate concentrations, such as loop diuretics. Similar studies should be performed to confirm our findings and to determine the optimal serum phosphate concentration in critically ill patients; the ideal phosphorus replacement strategy that incorporates the IV, oral, and enteral routes; the effect vasopressors have on absorption of phosphate via the oral route; diarrhea/complications of oral phosphate supplementations; and complications associated with the use of IV phosphate supplementation (eg, hypocalcemia, hypomagnesemia, and hypotension).
In conclusion, this study is the first to support that sufficient serum phosphate concentrations in critically ill patients can be achieved using oral or enteral phosphate products with no significant effect on MV-free hours or need for reintubation.
